Archive for Sunday, December 9, 2001

s pipeline

December 9, 2001


— Here are the eight Eli Lilly and Co. drugs the firm hopes to launch by the end of 2004, pending regulatory approval, with expected launch dates:

Forteo: A bone-building agent to reverse osteoporosis. 2002.

Cialis: Developed jointly with Bothell, Wash.-based ICOS Corp. to treat male erectile dysfunction. Late 2002.

Atomexetine: A nonstimulant to treat attention- deficit disorder in children. Late 2002.

Duloxetine: For depression. Late 2002.

Olanzipine and Fluoxetine combination: For treatment-resistant depression and psychotic depression. Submission for regulatory approval expected as early as 2002.

Alimta: For treatment of mesothelioma, a rare lung cancer linked to asbestos exposure. Submission for approval expected mid-2002.

Duloxetine: For stress urinary incontinence. Submission for approval late 2002.

PKC beta inhibitor: For treatment of diabetic macular edema and diabetic retinopathy, the leading cause of blindness in people under the age of 65. Submission for approval 2003.

Commenting has been disabled for this item.